BETA
Your AI-Trained Oncology Knowledge Connection!
Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC
The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.
Read More
Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer
Pembrolizumab Extends Survival in RCC: 5-Year Study Results
Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.
CREST Trial: Sasanlimab/BCG Improves NMIBC Outcomes
Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.
Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689
A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.
ELEVATE Trial: Elacestrant Combos Show Promise in ER+/HER2- Breast Cancer
The ELEVATE trial found combining elacestrant with everolimus or ribociclib is safe and effective for ER+/HER2- metastatic breast cancer.
Sacituzumab/Pembrolizumab Combo Shows Promise in Bladder Cancer
Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder cancer, enabling bladder preservation.
ENVISION: UGN-102 Shows Strong Response in Recurrent NMIBC
UGN-102 shows promising results in treating recurrent low-grade, intermediate-risk bladder cancer, with high response rates and manageable side effects.
Padeliporfin VTP Shows Promise for Low-Grade Upper Tract Urothelial Cancer
Interim results reveal padeliporfin VTP therapy as a promising, safe treatment for low-grade upper tract urothelial cancer, preserving kidney function.
BPd Combo Improves PFS & Response in High-Risk Relapsed/Refractory Myeloma
Combination therapy with BPd shows significant progression-free survival benefits in relapsed/refractory multiple myeloma patients with high-risk cytogenetic abnormalities.
Uncovering Social Disparities in Early-Onset Colorectal Cancer
A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved screening and early detection strategies.
Nivolumab/Relatlimab Shows Intracranial Activity in Melanoma Brain Mets
Nivolumab and relatlimab show promising intracranial activity in melanoma brain metastases, highlighting potential for further research in resistant cases.
Cell-Free DNA: Revolutionizing Breast Cancer Management and Screening
Massimo Cristofanilli, MD, discusses the role of cell-free DNA in breast cancer.
Watch
Pharmacist-Led Initiatives Drive Cost Reduction in Oncology Care
Zipalertinib Offers Promising Oral Option for EGFR Exon 20+ NSCLC
Zipalertinib shows promising efficacy and safety for advanced NSCLC with EGFR exon 20 mutations, offering a much-needed oral treatment option.
RET Inhibitor Rechallenge: Efficacy in NSCLC After Discontinuation
A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.
RP1/Nivolumab Shows Systemic Activity in Advanced Melanoma
New findings reveal RP1 combined with nivolumab enhances response rates in advanced melanoma, especially with deep tumor injections, showing promising safety and efficacy.
Insights From VERIFY: Rusfertide Shows Promise in Polycythemia Vera
A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.
FINER Trial: Ipatasertib Combo Extends PFS in ER+/HER2- Breast Cancer
Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative metastatic breast cancer patients post-CDK4/6 therapy.
Real-World Study Illuminates Waldenstrom Macroglobulinemia Outcomes
BNT327/Chemo Shows Durable Responses in Mesothelioma
A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.
Pembrolizumab Combo Promising for Unresectable Vulvar Cancer
A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable vulvar cancer.
THIO/Cemiplimab Combo Shows Activity in ICI-Resistant NSCLC
A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.
NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis
Novel Trispecific Antibody Delivers Efficacy and Safety in Myeloma
JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.
Adjuvant Encorafenib/Binimetinib Reduces Recurrence in BRAF-Mutant Melanoma
Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.
COMRADE Trial: Olaparib Plus Radium-223 Improves rPFS Survival in CRPC
In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.
Biomarkers Predict T-DXd Outcomes in Metastatic Breast Cancer
Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.
DKRd Improves Efficacy in Newly Diagnosed Multiple Myeloma
Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.
Cobolimab/Dostarlimab Combo Improves Responses in High-Risk Melanoma
Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.